BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22548340)

  • 1. A QSAR study on a series of pyrrole derivatives acting as lymphocyte-specific kinase (Lck) inhibitors.
    Anwer Z; Gupta SP
    Med Chem; 2012 Jul; 8(4):649-55. PubMed ID: 22548340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR.
    Takayama T; Umemiya H; Amada H; Yabuuchi T; Shiozawa F; Katakai H; Takaoka A; Yamaguchi A; Endo M; Sato M
    Bioorg Med Chem Lett; 2010 Jan; 20(1):108-11. PubMed ID: 19945869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ring-fused pyrazole derivatives as potent inhibitors of lymphocyte-specific kinase (Lck): Structure, synthesis, and SAR.
    Takayama T; Umemiya H; Amada H; Yabuuchi T; Koami T; Shiozawa F; Oka Y; Takaoka A; Yamaguchi A; Endo M; Sato M
    Bioorg Med Chem Lett; 2010 Jan; 20(1):112-6. PubMed ID: 19945867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validated quantitative structure-activity relationship analysis of a series of 2-aminothiazole based p56(Lck) inhibitors.
    Li J; Du J; Xi L; Liu H; Yao X; Liu M
    Anal Chim Acta; 2009 Jan; 631(1):29-39. PubMed ID: 19046675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I.
    Arnold LD; Calderwood DJ; Dixon RW; Johnston DN; Kamens JS; Munschauer R; Rafferty P; Ratnofsky SE
    Bioorg Med Chem Lett; 2000 Oct; 10(19):2167-70. PubMed ID: 11012021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II.
    Burchat AF; Calderwood DJ; Hirst GC; Holman NJ; Johnston DN; Munschauer R; Rafferty P; Tometzki GB
    Bioorg Med Chem Lett; 2000 Oct; 10(19):2171-4. PubMed ID: 11012022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P56(lck) kinase inhibitor studies: a 3D QSAR approach towards designing new drugs from flavonoid derivatives.
    Gunda SK; Narasimha SK; Shaik M
    Int J Comput Biol Drug Des; 2014; 7(2-3):278-94. PubMed ID: 24878734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
    Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
    J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of lymphocyte kinase Lck and phosphatidylinositol 3-kinase by a novel immunosuppressant, lymphostin.
    Nagata H; Yano H; Sasaki K; Sato S; Nakanishi S; Takahashi I; Tamaoki T
    Biosci Biotechnol Biochem; 2002 Mar; 66(3):501-7. PubMed ID: 12005041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disubstituted pyrimidines as Lck inhibitors.
    Hunt JA; Beresis RT; Goulet JL; Holmes MA; Hong XJ; Kovacs E; Mills SG; Ruzek RD; Wong F; Hermes JD; Park YW; Salowe SP; Sonatore LM; Wu L; Woods A; Zaller DM; Sinclair PJ
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5440-3. PubMed ID: 19674899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of p56(lck) tyrosine kinase by isothiazolones.
    Trevillyan JM; Chiou XG; Ballaron SJ; Tang QM; Buko A; Sheets MP; Smith ML; Putman CB; Wiedeman P; Tu N; Madar D; Smith HT; Gubbins EJ; Warrior UP; Chen YW; Mollison KW; Faltynek CR; Djurić SW
    Arch Biochem Biophys; 1999 Apr; 364(1):19-29. PubMed ID: 10087161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QSAR study of flavonoid derivatives as p56lck tyrosinkinase inhibitors.
    Thakur A; Vishwakarma S; Thakur M
    Bioorg Med Chem; 2004 Mar; 12(5):1209-14. PubMed ID: 14980632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck -- a selectivity insight.
    Burchat AF; Calderwood DJ; Friedman MM; Hirst GC; Li B; Rafferty P; Ritter K; Skinner BS
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1687-90. PubMed ID: 12039591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck).
    Wityak J; Das J; Moquin RV; Shen Z; Lin J; Chen P; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; Schieven GL; Kanner SB; Barrish JC
    Bioorg Med Chem Lett; 2003 Nov; 13(22):4007-10. PubMed ID: 14592495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosyl phosphorylation and activation of a type II phosphatidylinositol 4-kinase by p56(lck) in concanavalin A stimulated rat splenic lymphocytes.
    Fernandis AZ; Subrahmanyam G
    Mol Immunol; 2000 Apr; 37(6):273-80. PubMed ID: 11000401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cheng A; Faust T; Hsieh F; Huang X; Lee JH; Marshall TL; Martin MW; McGowan DC; Schneider S; Turci SM; White RD; Zhu X
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2305-9. PubMed ID: 17280833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
    Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA
    Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SVM model for virtual screening of Lck inhibitors.
    Liew CY; Ma XH; Liu X; Yap CW
    J Chem Inf Model; 2009 Apr; 49(4):877-85. PubMed ID: 19267483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.